Conditions: Recurrent Major Depressive Disorder With Atypical Features
Keywords: Depression Betahistine Dihydrochloride
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.

Detailed description:
All patients will start taking 50 mg of betahistine dihydrochloride on treatment day 1 (after baseline visit). Starting on day 4, the daily dose will be increased by adding a 50 mg dose. If tolerated, the daily dose will be titrated to 200 mg. At the end of week 3, the dose will be titrated to 300 mg.

Arms:
arm 1: Oral betahistine dihydrochloride; daily dose 50-300 mg

Interventions: intervention 1: betahistine dihydrochloride
Intervention descriptions: intervention 1: oral, 50-300 mg, daily

Protocol document: